At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

In early-stage trials, oral weight-loss drugs from Eli Lilly and Novo Nordisk have shown that they can help patients achieve ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Eli Lilly's new insulin data —Sanofi x Regeneron autoimmune drugs —Gilead's new AI partnership Get the full rundown here: ...

Eli Lilly is testing an experimental drug called orforglipron which ... However, some concerns remain about misuse, especially as pills can make it easier to take more than recommended. While side ...

Eli Lilly has posted a strong 8% increase in sales for the second quarter, led by growth of new products such as Trulicity, Taltz and Jardiance. However this upbeat story has been spoilt by a ...

She explains that Pfizer (PFE), Eli Lilly (LLY), and Novo are among the candidates who could offer weight loss drugs in pill form rather than through injection, which could transform the market.

As Eli Lilly and Novo Nordisk continue to dominate the lucrative weight-loss drug market, smaller competitors are gearing up ...

On the heels of Terns’ positive Phase I results that analysts compared with Lilly’s and Pfizer’s weight loss pills in ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

The weight-loss market is heating up as a number of companies are looking for a way to upend the dominance of market leaders Novo Nordisk ( NVO) and Eli Lilly ( LLY) by introducing GLP-1 pills.

Dushay cited hopes that pill versions of GLP-1 drugs could ease ... more important destination for lasting health benefits.” Eli Lilly will test just that, according to recently posted study ...